Harsh K Patel1, Alok A Khorana2. 1. Kansas City VA Medical Center, 4801 Linwood Blvd, Kansas City, MO, 64128, USA. 2. Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave./CA60, Cleveland, OH, 44195, USA. khorana@ccf.org.
Abstract
PURPOSE OF REVIEW: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients, and its management is often associated with complications including risk of recurrent VTE and bleeding. Here, we review the current data on pitfalls during anticoagulation in cancer patients and measures necessary to avoid them. RECENT FINDINGS: Although low-molecular-weight heparin monotherapy has been the standard of treatment for several years, emerging data for direct oral anticoagulants (DOACs) are leading to new paradigms in treatment. Reports of recent randomized trials suggest a lower risk of recurrent thrombosis but higher risk of bleeding, particularly in gastrointestinal cancer patients, with DOACs. Careful patient selection and individualization of therapy based on risk of bleeding as well as recurrent VTE are keys. Problems like bleeding, recurrence, thrombocytopenia, drug-drug interactions, renal impairment, nausea-vomiting along with concerns about adherence arise during anticoagulation in cancer patients. However, with adequate pre-treatment assessment, correct anticoagulant selection and proper monitoring during anticoagulation, these issues can be addressed safely and effectively.
PURPOSE OF REVIEW: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancerpatients, and its management is often associated with complications including risk of recurrent VTE and bleeding. Here, we review the current data on pitfalls during anticoagulation in cancerpatients and measures necessary to avoid them. RECENT FINDINGS: Although low-molecular-weight heparin monotherapy has been the standard of treatment for several years, emerging data for direct oral anticoagulants (DOACs) are leading to new paradigms in treatment. Reports of recent randomized trials suggest a lower risk of recurrent thrombosis but higher risk of bleeding, particularly in gastrointestinal cancerpatients, with DOACs. Careful patient selection and individualization of therapy based on risk of bleeding as well as recurrent VTE are keys. Problems like bleeding, recurrence, thrombocytopenia, drug-drug interactions, renal impairment, nausea-vomiting along with concerns about adherence arise during anticoagulation in cancerpatients. However, with adequate pre-treatment assessment, correct anticoagulant selection and proper monitoring during anticoagulation, these issues can be addressed safely and effectively.
Authors: Marc Carrier; Chris Cameron; Aurélien Delluc; Lana Castellucci; Alok A Khorana; Agnes Y Y Lee Journal: Thromb Res Date: 2014-10-08 Impact factor: 3.944
Authors: J Kooiman; P L den Exter; S C Cannegieter; S le Cessie; J del Toro; J C Sahuquillo; J M Pedrajas; M V Huisman Journal: J Thromb Haemost Date: 2013-11 Impact factor: 5.824
Authors: I Mahé; H Puget; J C Buzzi; M Lamuraglia; J Chidiac; A Strukov; Hélène Helfer; A Perozziello Journal: Support Care Cancer Date: 2016-03-16 Impact factor: 3.603
Authors: Ross Camidge; Bruno Reigner; Jim Cassidy; Susan Grange; Markus Abt; Erhard Weidekamm; Duncan Jodrell Journal: J Clin Oncol Date: 2005-07-20 Impact factor: 44.544
Authors: F Cajfinger; P Debourdeau; A Lamblin; V Benatar; N Falvo; Y Benhamou; M A Sevestre; D Farge-Bancel Journal: Thromb Res Date: 2016-06-09 Impact factor: 3.944
Authors: Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544
Authors: Andres Escobar; Ahmed M Salem; Kodwo Dickson; Tami N Johnson; Kathyrn J Burk; Lara Bashoura; Saadia A Faiz Journal: Support Care Cancer Date: 2022-05-17 Impact factor: 3.359
Authors: Spyridon Xynogalos; David Simeonidis; George Papageorgiou; Abraham Pouliakis; Nikolaos Charalambakis; Evangelos Lianos; Evridiki Mazlimoglou; Alexandros-Nikolaos Liatsos; Christos Kosmas; Nicolaos Ziras Journal: Support Care Cancer Date: 2022-05-12 Impact factor: 3.359
Authors: Mercedes Salgado; Elena Brozos-Vázquez; Begoña Campos; Paula González-Villarroel; María Eva Pérez; María Lidia Vázquez-Tuñas; David Arias Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 3.512